CODIAK BIOSCIENCES INC (CDAK)

US1920101060 - Common Stock

0.057  -0.07 (-55.98%)

After market: 0.0399 -0.02 (-30%)

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers for Tuesday morning with all the latest news traders need to know about!

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another dive into the biggest pre-market stock movers for Thursday with all the companies traders need to watch!

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday!

News Image
a year ago - InvestorPlace

Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?

Codiak BioSciences (CDAK) stock is falling hard on Monday after the company announced plans for an asset sale via a Chapter 11 bankruptcy.

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday!

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday!

News Image
a year ago - Codiak BioSciences, Inc.

Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

News Image
a year ago - Codiak BioSciences, Inc.

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated...

News Image
2 years ago - Codiak BioSciences, Inc.

Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses

– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 ...

News Image
2 years ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!

News Image
2 years ago - Codiak BioSciences, Inc.

Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company...

News Image
2 years ago - Codiak BioSciences, Inc.

Codiak Announces Proposed Public Offering of Common Stock and Warrants

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company...

News Image
2 years ago - Codiak BioSciences, Inc.

Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma –                   –...